Amplification, expression and rearrangement of c-myc and N-myc oncogenes in human lung cancer.
Amplification, expression and rearrangement of c-myc and N-myc oncogenes in human lung cancer.
复制标题
人肺癌中 c-myc 和 N-myc 癌基因的扩增、表达和重排。
DOI：
--
复制
发表时间：
1984
影响因子：
--
通讯作者：
J. Minna
中科院分区：
文献类型：
--
作者：
M. Nau;D. Carney;J. Battey;B. Johnson;C. Little;A. Gazdar;J. Minna
根据临床、组织学、生化和核型特征，人类肺癌可分为两大类：非小细胞肺癌(NSCLC)(腺癌、表皮样癌、大细胞癌)和“燕麦细胞”或小细胞肺癌(SCLC)(Minna 1982；Gazdar 1980；Baylin 1980；Gazdar 1981a；Wang Peng 1982 a)。特别令人感兴趣的是小细胞肺癌的一个子集，即形态和生化变体(SCLC-V)(Gazdar 1981a；Radice 1982；Carney 1983)。在给予任何化疗或放射治疗之前，在大约6-15%的诊断活检标本中可以看到这些变异(Radice 1982；Hirsch 1983)。在尸检中，大约30-40%的先前被认为在组织学上具有“纯”小细胞肺癌的患者将会有这些变异细胞。最后，在诊断活检中有变异细胞的患者有一个暴发性病程，对化疗和放射治疗的反应较差，比“纯”小细胞肺癌患者的生存期短得多(Radice 1982)。因此，这个SCLC-V组在临床上具有相当重要的意义。
Human lung cancers can be divided into two major classes according to their clinical, histological, biochemical, and karyotypic properties: non-small cell lung cancer (NSCLC) (adenocarcinoma, epidermoid, large cell carcinoma) and “oat cell” or small cell lung cancer (SCLC) (Minna 1982; Gazdar 1980; Baylin 1980; Gazdar 1981a; Whang Peng 1982a). Of particular interest is a subset of SCLC, the morphological and biochemical variants (SCLC-V) (Gazdar 1981a; Radice 1982; Carney 1983). These variants can be seen histologically in approximately 6-15% of diagnostic biopsy specimens before any chemo- or radiotherapy treatment is given (Radice 1982; Hirsch 1983). At autopsy, approximately 30–40% of patients previously thought to have “pure” SCLC histologically will have these variant cells. Finally, patients with variant cells in their diagnostic biopsies have a fulminant course with inferior response to chemo- and radiotherapy and a much shorter survival than patients with “pure” SCLC (Radice 1982). Thus, clinically this SCLC-V group is quite significant.